KUALA LUMPUR, Nov 9 (Bernama) -- AmMetLife Insurance Berhad (“AmMetLife”) and Pantai Premier Pathology Sdn. Bhd. (“Pantai Premier Pathology”) have signed a Memorandum of Understanding (MOU) extending their existing collaboration for two more years. Through this collaboration, AmMetLife’s medical plan customers will be able to access preferential rates when undergoing genomic testing for cancer at Pantai Premier Pathology’s network of 14 medical facilities across Malaysia.
The MOU covers 47 different tests, including BRCA for breast and ovarian cancer as well as EGFR for lung cancer, which can help to assist physicians in making more informed treatment decisions for cancer patients.
The MOU was signed by Lee Jiau Jiunn, Chief Executive Officer, AmMetLife and Hareeff Muhammed, Chief Executive Officer, Pantai Premier Pathology during a virtual ceremony attended by senior management and employees of both companies.
According to Lee, “The pandemic has driven greater awareness of people’s health and wellbeing. Individuals who may have never considered life or medical insurance before are now beginning to understand how it can support their family’s health and financial security. At AmMetLife, we are committed to supporting our customers navigate this health crisis by offering solutions that can help them make informed choices and seek the most effective treatment available. Through our ongoing collaboration with Pantai Premier Pathology, genomic testing is now easily accessible and affordable to many Malaysians suffering from cancer.”
Under this MOU, oncologists, cancer specialists and other medical professionals under Pantai Premier Pathology are able to provide AmMetLife customers with the relevant genomic tests and interpretation of results at preferential rates.
No comments:
Post a Comment